Accutar Biotech Stock
HealthTechLooking to sell Accutar Biotech stock or options?
Contact usFounded: 2015Funding to Date: $182M
Visit websiteAccutar Biotech is a developer of bio-pharmaceutical technology, aimed at hastening the process of drug discovery. The company employs computational drug design, supplemented by wet-lab validation. They offer services like ligand docking with side-chain flexibility, virtual screening, and prediction of a drug's ADME properties. This facilitates researchers in significantly reducing the time and expense typically involved in traditional drug discovery processes.
Investors Include:
Hedosophia, CMS Ventures, Karista (Paris), YITU, Mirae Asset Capital, 5Y Capital, Yunfeng Capital, 3W Partners Capital, Newton BioCapital, Primavera Capital Group, CDH Investments, ZhenFund, IDG Capital, Coatue Management.